|
Jun 14
|
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
|
|
Jun 14
|
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
|
|
Jun 13
|
AstraZeneca CFO: 'We've come a long way in our oncology portfolio'
|
|
Jun 13
|
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
|
|
Jun 13
|
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
|
|
Jun 13
|
FDA approves AstraZeneca’s Farxiga for paediatric T2D patients
|
|
Jun 12
|
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
|
|
Jun 12
|
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|
|
Apr 9
|
UK pharma companies told to make fewer drugs in draft net zero guidelines
|
|
Apr 8
|
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
|
|
Apr 8
|
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Solid Tumors
|
|
Apr 7
|
10 Best Weight Loss Drug Stocks to Buy Now
|
|
Apr 6
|
Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca PLC (LON:AZN)
|
|
Apr 6
|
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
|
|
Apr 6
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
|
|
Apr 5
|
15 Most Densely Populated Cities in Europe
|
|
Apr 5
|
Astrazeneca (AZN) Advances But Underperforms Market: Key Facts
|
|
Apr 5
|
AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study
|
|
Apr 5
|
Pharma Stock Roundup: AZN Voydeya Gets FDA Nod, MRK KRAS Inhibitor Enters Phase III
|
|
Apr 5
|
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
|